ArticleScientific reports2025
Exploring the link between the ZJU index and sarcopenia in adults aged 20-59 using NHANES and machine learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring the oral microbiome diversity and genus signatures associated with a novel non-invasive metabolic indicator: a cross-sectional study.The Saudi dental journal · 2026Article
- Correlation between ZJU index and sarcopenia in elderly inpatients and its predictive value.Frontiers in medicine · 2026Article
- Association between cardiometabolic index and sarcopenia: 2011-2018 National Health and Nutrition Examination survey (NHANES).Journal of clinical & translational endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sarcopenia, characterized by progressive loss of muscle mass and function, is a growing public health concern. The ZJU index, a novel metabolic marker, integrates lipid metabolism and glucose regulation parameters. While its association with metabolic disorders has been established, its relationship with sarcopenia remains underexplored, especially in middle-aged adults. This cross-sectional study analyzed data from 4,012 U.S. adults aged 20-59 years in the 2011-2018 NHANES dataset. The association between ZJU and sarcopenia was assessed using multivariable logistic regression, restricted cubic splines (RCS) for smooth curve fitting, and subgroup analyses. To improve risk stratification and identify key predictors, machine learning techniques-including Random Forest, SHAP, and the Boruta algorithm-were applied. Each standard deviation increase in ZJU was associated with an 13% higher likelihood of sarcopenia [OR = 1.13, 95% CI 1.08-1.17]. Individuals in the highest ZJU quartile faced a 12.6-fold greater likelihood than those in the lowest quartile [OR = 13.6, 95% CI 3.08-60.2]. Subgroup analysis showed notable interactions with gender and diabetes (p < 0.05). Machine learning models consistently ranked ZJU, education level, and race as the most influential predictors of sarcopenia, emphasizing the interplay between metabolic health and socioeconomic factors. Higher ZJU scores are linked to increased sarcopenia risk in adults aged 20-59 years, supporting its role as an early metabolic biomarker. Machine learning identified ZJU, education, and race as key predictors, underscoring the impact of socioeconomic factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.